COVID-19 Vaccine for Elderly: Should We Be Reactive or Proactive?

Siti Setiati, Jessica Marsigit

Abstract


It has been a year since the Indonesian government announced its first COVID-19 identified in Jakarta. Since then, there have been more than 900,000 cases in Indonesia with case fatality rate (CFR) of 2.9%. The number of new cases per day is now ranging from 9,000 cases to almost 13,000 cases. Not only in Indonesia, but the number of new cases along with the mortality rate in other countries, such as Malaysia, Japan, United States, and Europe region also increased dramatically.

COVID-19 vaccines are being investigated and the world hopes that vaccines will be the answer to tackle this pandemic. Is it really so? Immunization is an effort to induce immunity in individuals to prevent a disease or the complication related to the diseases that may be catastrophic. Immunization can be divided into passive, which is by giving certain type of antibody and active, which means that either we get the disease, or we get the antigen injected into our body.

Having prior vaccination or past COVID-19 does not mean that someone is totally immune to COVID-19 as a recent study suggested that the antibody related to COVID-19 past infection is significantly decreasing after 3 months post-infection. Compliance to implementation of health protocol remained the most crucial strategy during this pandemic.


Keywords


COVID-19; vaccine; elderly; COVID-19 vaccine

References


Komite Penanggulangan COVID-19 dan Pemulihan Ekonomi Nasional. Peta Sebaran. [cited on Jan 21 2021]. Available from: https://covid19.go.id/peta-sebaran.

Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond). 2007;57(8):552-6. doi: 10.1093/occmed/kqm110. PMID: 18045976.

Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent). 2005;18(1):21-25. doi:10.1080/08998280.2005.11928028.

Kay AW, Blish CA. Immunogenicity and Clinical Efficacy of Influenza Vaccination in Pregnancy. Front Immunol. 2015;6:289. Published 2015 Jun 4. doi:10.3389/fimmu.2015.00289

Singal AG, Higgins PD, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014;5(1):e45. Published 2014 Jan 2. doi:10.1038/ctg.2013.13.

Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020;52(5):737-741. doi:10.1016/j.immuni.2020.04.012

The New York Times. Coronavirus Vaccine Tracker. Updated Jan 19 2021. [cited on Jan 21 2021]. Available from: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html

Heaton PM. The Covid-19 Vaccine-Development Multiverse. N Engl J Med. 2020;383(20):1986-90.

Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603-15. DOI: 10.1056/NEJMoa2034577,

Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2035389

Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet .2021;397:99–111.

The Jakarta Globe. Indonesia approves Sinovac vaccine amid dramatic surge in Coronavirus cases. [cited on Jan 21 2021]. Available from: https://jakartaglobe.id/news/indonesia-approves-sinovac-vaccine-amid-dramatic-surge-in-coronavirus-cases.

Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021.

Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology. 2007;120(4):435-446. doi:10.1111/j.1365-2567.2007.02555.x

Nursyirwan SA, Koesno S, Wahyudi ER, Mansjoer A. Predictor factors affecting seroconversion post-influenza vaccination in the elderly. JPDI. 2017;4(4):204-208.

CNN. Norway reviewing deaths of frail and elderly patients vaccinated against Covid-19. [cited on Jan 21 2021]. Available from: https://edition.cnn.com/2021/01/18/health/covid-vaccine-pfizer-deaths-norway-intl/index.html.

Xue QL. The frailty syndrome: definition and natural history. Clin Geriatr Med. 2011;27(1):1-15. doi:10.1016/j.cger.2010.08.009.

Setiati, S., Laksmi, P.W., Aryana, I. et al. Frailty state among Indonesian elderly: prevalence, associated factors, and frailty state transition. BMC Geriatr 19, 182 (2019). https://doi.org/10.1186/s12877-019-1198-8.

Hewitt J, Carter B, Vilches-Moraga A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. Lancet Public Health. 2020;5:e444–51.

Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging. 2012;16(7):601-608. doi:10.1007/s12603-012-0084-2.

Searle SD, Mitnitski A, Gahbauer EA, et al. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8(24). https://doi.org/10.1186/1471-2318-8-24.

Mendiratta P, Latif R. Clinical Frailty Scale. [Updated 2021 Feb 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559009/.

Andrew MK, Shinde V, Ye L, et al. The importance of frailty in the assessment of trivalent inactivated influenza vaccine effectiveness against influenza-related hospitalization in elderly people. J Infect Dis. 2017;216(4):405–14.

Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5: 1598–607. https://doi.org/10.1038/s41564-020-00813-8.


Full Text: PDF

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Acta Medica Indonesiana